AR072051A1 - Compuestos que comprenden un grupo ciclobutoxi - Google Patents
Compuestos que comprenden un grupo ciclobutoxiInfo
- Publication number
- AR072051A1 AR072051A1 ARP090102018A ARP090102018A AR072051A1 AR 072051 A1 AR072051 A1 AR 072051A1 AR P090102018 A ARP090102018 A AR P090102018A AR P090102018 A ARP090102018 A AR P090102018A AR 072051 A1 AR072051 A1 AR 072051A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- group
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000003277 amino group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- -1 acylaminocarbonyl Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000005251 aryl acyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005253 heteroarylacyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Abstract
Procesos para prepararlos, composiciones farmaceuticas que comprenden dichos compuestos y su uso como productos farmaceuticos. Reivindicacion 1: Un compuesto de formula (1), isomeros geometricos, enantiomeros, diastereoisomeros, sales farmaceuticamente aceptables y todas las mezclas posibles de estos, caracterizado por A es un grupo amino sustituido o no sustituido que est enlazado a al grupo ciclobutilo a traves de un nitrogeno am¡nico; A1 es CH, C-halogeno, C-alcoxi o N; Y es O o S; B es un grupo amino sustituido o no sustituido que est enlazado a un grupo carbonilo o tiocarbonilo a traves de un nitrogeno am¡nico; X es O o S; y R1 es hidrogeno o alquilo C1-6 o halogeno o alcoxi C1-6; y con la condicion de que el compuesto de formula (1) sea diferente de N-(2-oxoazepan)-3-il)-4-{[trans-3-(piperidin-1-il)ciclobutil]oxi}benzamida; y con la condicion de que B sea un grupo amino diferente de -NH2; y con la condicion de que, cuando X es O e Y es O, B sea diferente de un grupo de formula (2), en la que R6 se selecciona del grupo que comprende o que consiste en sulfonilo, amino, alquilo C1-6 sustituido o no sustituido, alquenilo C2-6 sustituido o no sustituido, alquinilo C2-6 sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquilo C3-8 sustituido o no sustituido, heterocicloalquilo de 3-8 miembros sustituido o no sustituido, acilo, alquil C1-6-arilo sustituido o no sustituido, alquil C1-6-heteroarilo sustituido o no sustituido, alquenil C2-6-arilo sustituido o no sustituido, alquenil C2-6-heteroarilo sustituido o no sustituido, alquinil C2-6-arilo sustituido o no sustituido, alquinil C2-6-heteroarilo sustituido o no sustituido, alquil C1-6-cicloalquilo sustituido o no sustituido, alquil C1-6-heterocicloalquilo sustituido o no sustituido, alquenil C2-6-cicloalquilo sustituido o no sustituido, alquenil C2-6-heterocicloalquilo sustituido o no sustituido, alquinil C2-6-cicloalquilo sustituido o no sustituido, alquinil C2-6-heterocicloalquilo sustituido o no sustituido, alcoxicarbonilo, aminocarbonilo, alquil C1-6-carboxi sustituido o no sustituido, alquil C1-6-acilo sustituido o no sustituido, aril-acilo sustituido o no sustituido, heteroaril-acilo sustituido o no sustituido, (hetero)cicloalquil C3-8-acilo sustituido o no sustituido, alquil C1-6-aciloxi sustituido o no sustituido, alquil C1-6-alcoxi sustituido o no sustituido, alquil C1-6-alcoxicarbonilo sustituido o no sustituido, alquil C1-6-aminocarbonilo sustituido o no sustituido, alquil C1-6-acilamino sustituido o no sustituido, acilamino, acilaminocarbonilo, ureido, alquil C1-6-ureido sustituido o no sustituido, alquil C1-6-carbamato sustituido o no sustituido, alquil C1-6-amino sustituido o no sustituido, alquil C1-6-sulfoniloxi sustituido o no sustituido, alquil C1-6-sulfonilo sustituido o no sustituido, alquil C1-6-sulfinilo sustituido o no sustituido, alquil C1-6-sulfanilo sustituido o no sustituido, alquil C1-6-sulfonilamino sustituido o no sustituido, aminosulfonilo, alquil C1-6-aminosulfonilo sustituido o no sustituido, hidroxi, alquil C1-6-hidroxi sustituido o no sustituido, fosfonato, alquil C1-6-fosfonato sustituido o no sustituido, halogeno, ciano, carboxi, oxo y tioxo; R7 es Cl o NH2; y n es igual a 0, 1, 2, o 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5928508P | 2008-06-06 | 2008-06-06 | |
| EP08104281 | 2008-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072051A1 true AR072051A1 (es) | 2010-08-04 |
Family
ID=39929759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102018A AR072051A1 (es) | 2008-06-06 | 2009-06-05 | Compuestos que comprenden un grupo ciclobutoxi |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20110098300A1 (es) |
| EP (1) | EP2300426A1 (es) |
| JP (1) | JP2011524344A (es) |
| KR (1) | KR20110033149A (es) |
| CN (1) | CN102083792A (es) |
| AR (1) | AR072051A1 (es) |
| AU (1) | AU2009253961A1 (es) |
| BR (1) | BRPI0912118A2 (es) |
| CA (1) | CA2723626A1 (es) |
| CO (1) | CO6331428A2 (es) |
| EA (1) | EA201001855A1 (es) |
| IL (1) | IL208952A0 (es) |
| MA (1) | MA32374B1 (es) |
| MX (1) | MX2010013405A (es) |
| TW (1) | TW201010995A (es) |
| UY (1) | UY31871A (es) |
| WO (1) | WO2009147149A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| CN103382174A (zh) | 2006-06-23 | 2013-11-06 | 雅培制药有限公司 | 作为组胺h3受体调节物的环丙胺衍生物 |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| WO2012037258A1 (en) | 2010-09-16 | 2012-03-22 | Abbott Laboratories | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| US10709692B2 (en) * | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) * | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10226462A1 (de) * | 2002-06-13 | 2003-12-24 | Aventis Pharma Gmbh | Fluorierte Cycloalkyl-derivatisierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| JP2008543923A (ja) * | 2005-06-22 | 2008-12-04 | ファイザー・プロダクツ・インク | ヒスタミン−３受容体アンタゴニスト |
-
2009
- 2009-06-02 JP JP2011512102A patent/JP2011524344A/ja not_active Withdrawn
- 2009-06-02 MX MX2010013405A patent/MX2010013405A/es not_active Application Discontinuation
- 2009-06-02 CA CA2723626A patent/CA2723626A1/en not_active Abandoned
- 2009-06-02 WO PCT/EP2009/056758 patent/WO2009147149A1/en active Application Filing
- 2009-06-02 EA EA201001855A patent/EA201001855A1/ru unknown
- 2009-06-02 BR BRPI0912118A patent/BRPI0912118A2/pt not_active Application Discontinuation
- 2009-06-02 US US12/995,084 patent/US20110098300A1/en not_active Abandoned
- 2009-06-02 EP EP09757530A patent/EP2300426A1/en not_active Withdrawn
- 2009-06-02 KR KR1020107029650A patent/KR20110033149A/ko not_active Application Discontinuation
- 2009-06-02 CN CN2009801206649A patent/CN102083792A/zh active Pending
- 2009-06-02 AU AU2009253961A patent/AU2009253961A1/en not_active Abandoned
- 2009-06-04 TW TW098118528A patent/TW201010995A/zh unknown
- 2009-06-05 AR ARP090102018A patent/AR072051A1/es unknown
- 2009-06-05 UY UY0001031871A patent/UY31871A/es unknown
-
2010
- 2010-10-26 IL IL208952A patent/IL208952A0/en unknown
- 2010-12-03 MA MA33390A patent/MA32374B1/fr unknown
-
2011
- 2011-01-06 CO CO11001366A patent/CO6331428A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0912118A2 (pt) | 2015-11-03 |
| MX2010013405A (es) | 2011-02-15 |
| EP2300426A1 (en) | 2011-03-30 |
| KR20110033149A (ko) | 2011-03-30 |
| TW201010995A (en) | 2010-03-16 |
| UY31871A (es) | 2010-01-29 |
| MA32374B1 (fr) | 2011-06-01 |
| US20110098300A1 (en) | 2011-04-28 |
| CN102083792A (zh) | 2011-06-01 |
| IL208952A0 (en) | 2011-01-31 |
| AU2009253961A1 (en) | 2009-12-10 |
| WO2009147149A1 (en) | 2009-12-10 |
| CO6331428A2 (es) | 2011-10-20 |
| JP2011524344A (ja) | 2011-09-01 |
| CA2723626A1 (en) | 2009-12-10 |
| EA201001855A1 (ru) | 2011-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072051A1 (es) | Compuestos que comprenden un grupo ciclobutoxi | |
| CO6321170A2 (es) | Heterociclos fusionados de ciclobutoxi amino y usos terapeuticos de los mismos | |
| HRP20090061T3 (en) | Purine derivatives acting as a2a receptor agonists | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR059201A1 (es) | Compuestos citotoxicos derivados de tomaimicina | |
| CO6150145A2 (es) | Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR058554A1 (es) | Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5. | |
| AR063311A1 (es) | Compuestos organicos | |
| AR058404A1 (es) | Derivados diamina como inhibidores de leucotrieno a4 hidrolasa | |
| WO2008146871A1 (ja) | グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体 | |
| AR074773A1 (es) | Piridazinonas sustituidas con fenilo en la posicion 4, su utilizacion como herbicidas e insecticidas en composiciones y metodos que los incluyen e intermediarios para su sintesis. | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
| AR086474A1 (es) | Compuestos de pirazol pesticidas | |
| EA201070874A1 (ru) | Производные индол-2-карбоксамидов и азаиндол-2-карбоксамидов, замещённых силанильной группой, их получение и применение в терапии | |
| CU20090040A7 (es) | Compuestos de 4-metil piridopirimidinona | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| ECSP11011164A (es) | Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapéutica | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| AR077363A1 (es) | DERIVADOS DE 1,2,3,4- TETRAHIDRO-PIRIMIDO{1,2-A} PIRIMIDIN-6-ONA, SU PREPARACIoN, SU UTILIZACIoN EN QUIMIOTERAPIA Y SUS COMPOSICIONES FARMACEUTICAS. | |
| AR077364A1 (es) | Derivados de 6-oxo-1,6- dihidro -pirimidin-2-il-) amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |